Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.

Biotechnology

Delix Therapeutics

Mark Rus

Milan Chytil

Kurt Rasmussen

Eliseo Salinas

Matt Gorman

Tricia Mccall

Sharon Engel

Retsina Meyer

David Olson

The Leadership Team at Delix Therapeutics is responsible for steering the company’s strategic vision and operational execution in developing innovative, non-hallucinogenic psychedelic therapies. Comprising executives from diverse backgrounds, including scientific research, corporate governance, and human resources, the team collaborates to drive progress through preclinical and clinical stages, ensuring alignment with regulatory standards while fostering a culture of innovation and ethical responsibility in addressing mental health challenges.

Leadership Team

Advisory

Corporate Strategy

Leadership Team

About

Team members

Other teams at Delix Therapeutics

Advisory

Corporate Strategy